Early n = 101 | Late n = 104 | P-value | |
---|---|---|---|
Sex, male | 73 (72%; 63 to 81) | 63 (61%; 50 to 70) | 0.0763 |
Age, years | 65 (19 to 84) | 68.5 (20 to 88) | 0,3229 |
SAPS 2 | 38 (9 to 78) | 37 (10 to 85) | 0.8156 |
Probability of death (SAPS 2) | 0.21 (0.01, 0.91) | 0.20 (0.01, 0.95) | 0.8083 |
SAPS 3 | 58 (31 to 114) | 60 (32 to 105) | 0.6906 |
Probability of death (SAPS 3) | 0.32 (0.02, 0.96) | 0.36 (0.02, 0.93) | 0.6932 |
APACHE II | 20 (7 to 37) | 19 (8 to 38) | 0.5508 |
ISS, n | 29 (16 to 57) [17] | 31 (25 to 59) [10] | 0.8204 |
SOFA admission | 8 (1 to 17) | 9 (1 to 20) | 0.3666 |
SOFA decision | 6 (2 to 17) | 7 (2 to 15) | 0.5511 |
Difference between SOFA | 2 (-7 ; 9) | 2 (-5 ; 10) | 0.2849 |
Elective surgery | 34 (33.7%; 25 to 44) | 32 (30.8%; 22 to 41) | 0.6575 |
Trauma | 17 (16.8%; 10 to 26) | 10 (9.6%; 5 to 17) | 0.1266 |
Emergency surgery | 12 (11.9%; 6 to 20) | 21 (20.2%; 13 to 29) | 0.1055 |
Medical condition | 38 (37.6%; 28 to 48) | 41 (39.4%; 30 to 50) | 0.7913 |
Inhaled nitric oxide | 12 (12%; 6 to 20) | 13 (12.5%; 6 to 19) | 0.8923 |
Prone decubitus | 9 (9%; 4 to 16) | 13 (12.5%; 7 to 21) | 0.4065 |
Swan-Ganz catheter | 17 (17%; 10 to 26) | 17 (16%; 10 to 25) | 0.9003 |
Renal replacement techniques | 10 (10%; 4 to 17) | 18 (17%; 11 to 26) | 0.1226 |
Vasoactive drugs | 84 (83%; 74 to 90) | 95 (91%; 84 to 96) | 0.0786 |
Parenteral nutrition | 26 (26%; 17 to 35) | 25 (24%; 16 to 33) | 0.7778 |
Intracranial pressure monitoring | 17 (17%; 10 to 26) | 8 (8%; 3 to 15) | 0.0456 |
Circulatory assist | 6 (6%; 2 to 12) | 6 (6%; 2 to 12) | 0.9583 |
Main reason for ventilatory support | |||
Acute respiratory insufficiency | 68 (67.3%; 56 to 76) | 72 (69.2%; 59 to 78) | 0.7696 |
Neuromuscular illness | 3 (3%; 0.6, 9) | 2 (1.9%; 0.2, 7) | 0.6270 |
Coma (Glasgow coma scale <10) | 27 (26.7%; 19 to 37) | 20 (19.2%; 12 to 28) | 0.2014 |
Decompensated COPD | 3 (3%; 0.6, 9) | 9 (8.6%; 4 to 16) | 0.0831 |
Acute asthma attack | 0 | 0 | |
Other respiratory disease | 0 | 1 |